Related Experiment Videos
Selective gene expression in hepatic tumor with trans-arterial delivery of DNA/liposome/transferrin complex
1Cancer Research Center, Seoul National University College of Medicine, Korea.
Abstract:
Since hepatocellular carcinoma (HCC) is frequently presented at an advanced stage, only a small portion of patients with HCC can be treated with local modalities. Gene therapy is, therefore, one of the more promising approaches for patients with advanced HCC. To develop a new strategy for targeting gene delivery to the hepatic tumor, the efficiency of the transarterial delivery of liposome-DNA complex was evaluated in VX2 carcinoma implanted into the liver of rabbits. A mixture of pSV-beta galactosidase plasmid (40 micrograms), lipofectin (80 microliters), and transferrin (852 micrograms), the optimal proportion of which determined in vitro, was infused via the hepatic artery of a rabbit with VX2 hepatic tumors. The efficiency of trans-arterial gene delivery was compared to that of intra-tumoral injection. Rabbits (5 in each group) were sacrificed 48 hours after gene delivery and hepatic tissues were examined using X-gal staining. beta-galactosidase staining was observed exclusively within the tumor following the trans-arterial gene transfer. In contrast, adjacent peritumoral cells in addition to hepatic tumor cells were transfected by the intra-tumoral injection of transgene. These data indicate that enhanced gene expression in hepatic tumors is possible using trans-arterial delivery of the liposome-DNA complex.
Insights
Transarterial gene delivery using liposome-DNA complexes effectively targets liver tumors in rabbits. This method enhances gene expression specifically within hepatic tumors, offering a promising approach for advanced hepatocellular carcinoma treatment.
Area of Science:
- Oncology
- Gene Therapy
- Biotechnology
Background:
- Hepatocellular carcinoma (HCC) often presents at advanced stages, limiting treatment options.
- Gene therapy offers a promising avenue for treating advanced HCC.
- Targeted gene delivery to hepatic tumors is crucial for effective therapy.
Purpose of the Study:
- To evaluate the efficiency of transarterial delivery of liposome-DNA complexes for targeting hepatic tumors.
- To compare transarterial gene delivery with direct intra-tumoral injection.
- To assess the potential of this method for advanced HCC treatment.
Main Methods:
- VX2 carcinoma was implanted into the livers of rabbits.
- A liposome-DNA complex (pSV-beta galactosidase plasmid, lipofectin, transferrin) was infused via the hepatic artery.
- Gene delivery efficiency was assessed by comparing transarterial infusion with intra-tumoral injection.
- X-gal staining was used to detect beta-galactosidase expression 48 hours post-delivery.
Main Results:
- Transarterial gene delivery resulted in beta-galactosidase staining exclusively within the hepatic tumor.
- Intra-tumoral injection led to transfection of both tumor cells and adjacent peritumoral cells.
- This indicates a higher degree of tumor-specific gene expression with the transarterial approach.
Conclusions:
- Transarterial delivery of liposome-DNA complexes provides enhanced gene expression specifically in hepatic tumors.
- This targeted approach holds significant potential for the gene therapy of advanced hepatocellular carcinoma.
- Further research into optimizing this delivery method is warranted.